Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Report Date: February 27, 2025
Period Covered: Fiscal fourth quarter and fiscal year ended December 31, 2024.
This filing serves to announce the release of financial results for the specified period via a press release incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release attached as Exhibit 99.1, which is referenced but not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the announcement of results but does not include specific management commentary, guidance, or outlook within the 8-K text itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt. The filing notes that the information in the press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for that specific content.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 27, 2025) for actual revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter performance trends in the attached press release.
- Check for any forward-looking statements or updated guidance provided in the press release.
- Confirm the status of the company's liquidity and debt obligations as detailed in the full financial report.